Courtesy of Benzinga.
QIAGEN (NASDAQ: QGEN) announces European launch of therascreen® IDH1/2 test for gliomas as well as a IDH1/2-related collaboration with Mayo Clinic · QIAGEN’s therascreen® IDH1/2 RGQ Kit is the first CE-marked test targeting IDH1 and IDH2 biomarkers to diagnose brain gliomas and assess prognoses · Partnership with Mayo Clinic aims to develop tools for personalized medicine in cholangiocarcinoma, or bile duct cancer HILDEN, Germany, and MARSEILLE, France, January 06, 2013 – QIAGEN N.V. today announced the European launch of its new therascreen® IDH1/2 RGQ Kit, enabling physicians to better diagnose and assess the prognoses of patients with gliomas, or tumors of the brain and spinal cord. The test is based on QIAGEN’s proprietary biomarkers for IDH1 and IDH2 gene mutations. The therascreen® IDH1/2 RGQ Kit has received CE marking enabling marketing in Europe and certain other markets. In addition, QIAGEN announced a new collaboration with Mayo Clinic to develop diagnostics for cholangiocarcinoma (CCA), also known as bile duct cancer, using biomarkers for the IDH1 and IDH2 mutations. The therascreen IDH1/2 RGQ PCR Kit enables detection of 12 mutations in the IDH1 and IDH2 genes in a single test using real-time PCR. Mutations in IDH1/2 are recognized as prognostic markers for
